J&J executive committee changes; chairman to retire

25 June 2018

US health care giant Johnson & Johnson (NYSE: JNJ) has announced the appointment of a number of senior leaders to the company's executive committee.

Specifically:

Joaquin Duato, executive vice president, worldwide chairman, Pharmaceuticals, and Dr Paul Stoffels, EVP, chief scientific officer of Johnson & Johnson have been appointed to the position of vice chairman of the executive committee, effective July 2, 2018. Mr Duato and Dr Stoffels will continue to report to Alex Gorsky, chief executive of J&J.

In their new roles, Mr Duato will be responsible for the Pharmaceuticals and Consumer sectors, as well as Supply Chain, IT, Global Services, and the Health and Wellness businesses, while Dr Stoffels will be responsible for Pharmaceutical R&D, Global Public Health, the office of the chief medical officer, external innovation, pharmaceuticals business Development and Healthcare Technology.

Ashley McEvoy, company group chairman, Consumer Medical Devices, has been appointed EVP, worldwide chairman, Medical Devices, effective July 2, 2018. She will report to Mr Gorsky and become a member of the executive committee.

Jennifer Taubert, company group chairman, The Americas, Pharmaceuticals, has been appointed EVP, worldwide chairman, Pharmaceuticals and named to the executive committee, effective July 2, 2018, reporting to Mr Duato.

Kathy Wengel, worldwide VP, Johnson & Johnson Supply Chain has been appointed EVP, chief global supply chain officer, and named to the executive committee, effective July 2, 2018. She will report to Mr. Duato.

Michael Sneed, worldwide VP, global corporate affairs and chief communication officer, will become EVP, global corporate affairs and CCO and a member of the executive committee, effective July 2, 2018. Mr Sneed will also assume responsibility for the Global Design group and will continue to report to Mr Gorsky.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK